455 documents

Read All
21:05 , Mar 25, 2019 |  BC Extra  |  Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia. AVP-786 comprises deuterium-modified dextromethorphan --...
Read More
22:14 , Feb 21, 2019 |  BC Extra  |  Company News

Management tracks: Mirati, Verastem, RedHill

Oncology company Mirati Therapeutics Inc. (NASDAQ:MRTX) named Faheem Hasnain as chairman. He succeeds Rodney Lappe, who is retiring but will remain a consulting adviser. Hasnain is executive chairman of Gossamer Bio Inc. (NASDAQ:GOSS), which raised...
Read More
19:27 , Dec 21, 2018 |  BC Week In Review  |  Company News

Otsuka's Avanir to terminate Onzetra license

OptiNose Inc. (NASDAQ:OPTN) said it received written notice from Avanir Pharmaceuticals Inc. that the latter intends to terminate, effective March 10, a license granting it rights to develop and commercialize migraine drug Onzetra Xsail in...
Read More
19:23 , Oct 26, 2018 |  BC Week In Review  |  Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
Read More
22:52 , Oct 25, 2018 |  BC Extra  |  Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
Read More
19:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on July 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope...
Read More
18:50 , Jul 11, 2018 |  BC Extra  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...
Read More
22:35 , Jun 25, 2018 |  BC Extra  |  Company News

Management tracks: Nordic Nanovector, Molecular Partners

Cancer company Nordic Nanovector ASA (OSE:NANO) hired Eduardo Bravo as CEO, effective July 2. He was CEO at TiGenix N.V. (NASDAQ:TIG; Euronext:TIG). Protein therapeutics company Molecular Partners AG (SIX:MOLN) said CSO Michael Stumpp has become...
Read More
22:05 , Apr 25, 2018 |  BC Extra  |  Company News

Management tracks: Urovant, Cue

Urology company Urovant Sciences, a subsidiary of Roivant Sciences GmbH (Basel, Switzerland), hired Cornelia Haag-Molkenteller as CMO, Michael McFadden as chief commercial officer, Bryan Smith as general counsel and Christine Ocampo as SVP and chief...
Read More
23:45 , Sep 27, 2017 |  BC Extra  |  Company News

Management tracks: Gilead, Tango, Rubius, Bicycle

Gilead Sciences Inc. (NASDAQ:GILD) said COO Kevin Young will retire, effective early 2018. Young returned to Gilead as COO in May 2016 after brief retirement during which he acted as an advisor. He was Gilead's...
Read More